OptimizeRx (OPRX) Posts Earnings Results, Meets Expectations

OptimizeRx (OTCMKTS:OPRX) released its earnings results on Tuesday, August 7th. The technology company reported $0.02 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.02, Fidelity Earnings reports. The firm had revenue of $5.10 million for the quarter, compared to analyst estimates of $4.34 million. OptimizeRx had a negative return on equity of 22.08% and a negative net margin of 10.02%.

OPRX traded down $0.02 during trading on Friday, hitting $12.76. The company’s stock had a trading volume of 27,570 shares, compared to its average volume of 32,909. OptimizeRx has a 12 month low of $2.30 and a 12 month high of $12.74. The company has a market cap of $120.07 million, a price-to-earnings ratio of -60.76 and a beta of 0.53.

A number of brokerages have commented on OPRX. Lake Street Capital raised their price objective on OptimizeRx to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. B. Riley raised their price objective on OptimizeRx from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Zacks Investment Research upgraded OptimizeRx from a “hold” rating to a “strong-buy” rating and set a $15.00 price objective for the company in a research report on Tuesday, August 21st. Finally, Roth Capital reiterated a “buy” rating on shares of OptimizeRx in a research report on Monday, June 18th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $15.33.

In other news, President Miriam J. Paramore bought 5,000 shares of the stock in a transaction dated Friday, June 15th. The stock was bought at an average cost of $8.07 per share, with a total value of $40,350.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Douglas P. Baker sold 4,784 shares of OptimizeRx stock in a transaction on Friday, August 10th. The shares were sold at an average price of $12.01, for a total value of $57,455.84. The disclosure for this sale can be found here. In the last quarter, insiders acquired 7,995 shares of company stock valued at $71,691.

OptimizeRx Company Profile

OptimizeRx Corporation provides digital health messaging to the pharmaceutical industry. The company offers a direct channel for pharmaceutical companies to communicate with healthcare providers. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-Prescribe systems to search, print, or electronically dispense directly to patients, as well as a network of pharmacies; and brand messaging services, such as various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages that could be targeted by specialty, diagnostic code, and other criteria.

Featured Article: Risk Tolerance and Your Investment Decisions

Earnings History for OptimizeRx (OTCMKTS:OPRX)

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply